CLINICAL POLICY: Humira (adalimumab)
EFFECTIVE DATE: 01/01/2024
LAST REVIEW DATE: 10/15/2024

I. INDICATIONS
Humira is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Plaque Psoriasis
- Hidradenitis Suppurativa
- Uveitis

II. CRITERIA FOR INITIAL APPROVAL
Humira may be approved when ALL of the following criteria are met:

1. Diagnosis: Patient has ONE of the following confirmed diagnoses:
   a. Moderately to severely active rheumatoid arthritis
   b. Active psoriatic arthritis
   c. Active ankylosing spondylitis
   d. Moderately to severely active Crohn's disease
   e. Moderately to severely active ulcerative colitis
   f. Chronic plaque psoriasis covering ≥ 3% body surface area
   g. Moderate to severe hidradenitis suppurativa
   h. Non-infectious intermediate, posterior, or panuveitis

2. Age Requirement: Patient is ≥ 18 years of age (or ≥ 6 years for certain pediatric indications)

3. Prior Therapy Requirement:
   a. For RA, PsA, or AS: Trial and failure of at least TWO conventional DMARDs (e.g., methotrexate, sulfasalazine, leflunomide) for ≥ 3 months each, unless contraindicated
   b. For Crohn's or UC: Trial and failure of conventional therapy (e.g., corticosteroids, immunomodulators) for ≥ 8 weeks
   c. For Plaque Psoriasis: Trial and failure of at least ONE systemic therapy (e.g., methotrexate, cyclosporine, acitretin) or phototherapy
   d. For Hidradenitis Suppurativa: Trial and failure of oral antibiotics

4. Baseline Testing: Patient has completed ALL of the following within 90 days:
   a. Tuberculosis screening (TB skin test or QuantiFERON Gold)
   b. Hepatitis B and C screening
   c. Complete blood count (CBC)
   d. Liver function tests (AST, ALT)

5. Contraindications: Patient does NOT have any of the following:
   a. Active infection requiring systemic treatment
   b. Active tuberculosis or latent TB without appropriate prophylaxis
   c. Moderate to severe heart failure (NYHA Class III/IV)
   d. Demyelinating disease (e.g., multiple sclerosis)
   e. Current malignancy (except adequately treated non-melanoma skin cancer)

6. Prescriber Requirement: Prescribed by or in consultation with a specialist appropriate for the condition:
   a. Rheumatologist (for RA, PsA, AS)
   b. Gastroenterologist (for Crohn's, UC)
   c. Dermatologist (for psoriasis, HS)
   d. Ophthalmologist (for uveitis)

III. DURATION OF APPROVAL
Initial approval: 6 months
Renewal approval: 12 months

IV. RENEWAL CRITERIA
For renewal, the following must be demonstrated:
1. Clinical Response: Documentation of positive clinical response, including:
   a. For RA/PsA/AS: Improvement in disease activity scores (e.g., DAS28, ACR20)
   b. For IBD: Reduction in disease activity index scores
   c. For Psoriasis: Improvement in PASI score or BSA affected
   d. For HS: Reduction in inflammatory nodules and abscesses
2. Absence of treatment-limiting adverse effects
3. Updated TB screening annually
4. Continued follow-up with appropriate specialist